SERB - About the company
SERB is a funded company based in Brussels (Belgium), founded in 1950. It operates as a R&D company focused on manufacturing specialty drugs for multiple therapeutic areas.
Company Details
- Website
- serb.com
- Social
Key Metrics
Founded Year
1950
Location
Brussels, Belgium
Stage
Funding Raised
Investors
Annual Revenue
€50M - €100M as on Dec 31, 2024
Employee Count
582 as on Sep 30, 2026
Investment & Acquisitions
Legal entities associated with SERB
SERB is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
SERB CIN: 0538.813.719 , Belgium, Active | Sep 19, 2013 | €50M - €100M (As on Dec 31, 2024) | 9 (As on Dec 31, 2022) | - |
Sign up to download SERB's company profile
SERB's funding and investors
SERB is a funded company. SERB has 2 institutional investors.
View details of SERB's funding rounds and investors
SERB's founders and board of directors
Founder? Claim ProfileSERB's employee count trend
SERB has 582 employees as of Sep 26. Here is SERB's employee count trend over the years:
Uncover SERB's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
SERB's Investments and acquisitions
SERB has acquired 3 companies including Y-mAbs Therapeutics, VISTOGARD® and Xuriden. SERB has not made any investments as of now.Here is the list of its acquisitions:
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Aug 05, 2025 | Acquisition | 2014 | New York City (United States) | |
Jul 13, 2023 | Acquisition | 2011 | Rockville (United States) | |
Jul 13, 2023 | Acquisition | 2011 | Rockville (United States) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by SERB
Reports related to SERB
Here is the latest report on SERB's sector:
News related to SERB
Filter this listMedia has covered SERB for a total of 11 events in the last 1 year, 2 of them have been about company updates and 2 about partnerships.
•
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa BiopharmaGlobeNewswire•Jul 01, 2026•Hansa Biopharma, SERB
•
•
SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the USGlobeNewswire•May 07, 2026•SERB
•
Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical OfficerGlobeNewswire•Nov 17, 2025•SERB
•
SERB Pharmaceuticals Completes Acquisition of Y-mAbs TherapeuticsGlobeNewswire•Sep 16, 2025•SERB, Y-mAbs Therapeutics
•
SERB Pharmaceuticals to Acquire Y-mAbs TherapeuticsForexTV•Aug 05, 2025•SERB, Y-mAbs Therapeutics, Monteverde, DistributionNOW and 2 others
•
Bentracimab successfully reverses Ticagrelor's antiplatelet effects in surgery/bleeding patients (Phase 3 trial).GlobeNewswire•Mar 29, 2025•SFJ Pharmaceuticals, SERB
•
First FDA-approved treatment for severe frostbite now commercially available in the USGlobeNewswire•Dec 09, 2024•SERB
•
•
FDA gives SFJ and SERB’s bentracimab BLA priority reviewPharmaceutical Technology•Aug 05, 2024•SFJ Pharmaceuticals, SERB
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about SERB
Explore our recently published companies
- Its Better Over Here - Unfunded company
- Julia Broder - Westport based, Unfunded company
- Ocean Decisions - Unfunded company
- Introspeck Management - Philippines based, 2024 founded, Unfunded company
- Maserati Las Vegas - Unfunded company
- Gonzalez Roverano - Unfunded company
